




MOLECULAR TARGETING TECHNOLOGIES, INC.
Translating Novel Technologies into Tomorrow's Medicines

TDURA (^{99m}Tc-duramycin)

A New Tool for Early Imaging of Disease and Drug Response



Tumor response visualized 24 hours after drug application; no response in treatment resistant mice

Source: J Nucl Med.
doi:10.2967/jnumed.116.182014

1st prize of 2017 Image of the Year award at the Society of Nuclear Medicine & Molecular Imaging
2nd prize in 2017 Innovation Challenge at RESI Boston

MTTI licensed TDURA from the Medical College of Wisconsin

Challenges

Seeing drug response in cancer treatment and other disease states takes weeks, negatively affecting outcomes.

Solution

Imaging with TDURA gives actionable diagnostics for drug treatment response in one day. It penetrates and clears readily.

Technology

Duramycin, a small protein (2000 Da), binds to phosphatidylethanolamine with high (5nm) affinity and selectivity. TDURA visualizes dead and dying cells.

Proof of Concept

Extensive preclinical studies visualizing:
CANCER

- Colorectal cancer response to therapy
- Breast cancer response to therapy
- Cardiotoxicity due to chemotherapy

HEART DISEASE

- Atherosclerotic plaque
- Acute MI
- Stroke
- Transplant rejection

INFLAMMATION: Systemic Inflammatory Response Syndrome

PULMONARY DISEASE: ARDS

Funding

- NIH Phase 2 SBIR for manufacture & Phase 0/1 trials (Univ of Antwerp)
- MTT Holding Co. financing admin.

Next

- cGMP manufacture – in process through Q3 2019
- eIND enabling study – Q3 2019
- Phase 0/I trials – Q4 2019 (Univ. of Antwerp)
- Phase II trials - 2021

MTTI

Molecular Targeting Technologies, Inc. is a privately held biotechnology company focused on the acquisition and development of novel technologies for treatment and diagnosis of human diseases.

Two radiotherapeutics and two radiodiagnostics lead our 10-asset pipeline.

Contact: cpak@mtarget.com

More information: www.mtarget.com.